文献速递慢性肾脏病肾血管病与高血压

抑制肾素-血管紧张素系统时肾小球滤过率的急性变化不能预测随后的肾脏和心血管结局

Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
PubMed 文献 · Kidney Int · 2016-12-04

对ONTARGET和TRANSCEND试验中9340例新启用肾素-血管紧张素系统阻滞剂的患者进行事后分析,中位随访56个月。起始阻滞剂后2周肾小球滤过率下降≥15%者1480例(16%),8周持续者700例(7%)。肾小球滤过率急性升高或降低均与心血管结局和微量白蛋白尿风险增加呈多无统计学显著的趋势相关,且不能预测治疗获益。

要点

  • 起始肾素-血管紧张素系统阻滞剂后2周肾小球滤过率下降≥15%者占16%,8周持续者占7%。
  • 肾小球滤过率急性升高或降低与心血管结局风险增加呈多无统计学显著的趋势相关。
  • 肾小球滤过率急性变化与替米沙坦的肾脏或心血管获益无交互作用。

核心结论

  • 起始肾素-血管紧张素系统阻滞剂后肾小球滤过率升高和降低均常见,可能与心血管和肾脏结局风险增加弱相关,但变化不能预测治疗获益增加。

研究设计与样本

  • 对ONTARGET和TRANSCEND两项随机对照试验的事后分析,纳入有血管疾病或血管疾病风险的患者,中位随访56个月。
  • 分析9340例新启用肾素-血管紧张素系统阻滞剂并随机接受该阻滞剂的患者。
  • 分析TRANSCEND中3000余例随机接受替米沙坦或安慰剂的患者。

主要发现

  • 起始肾素-血管紧张素系统阻滞剂后2周肾小球滤过率下降≥15%者1480例(16%),8周持续者700例(7%)。
  • 心血管结局发生于1280例参与者,微量白蛋白尿发生于864例参与者。
  • 肾小球滤过率急性升高和降低均与心血管结局和微量白蛋白尿风险增加呈多无统计学显著的趋势相关。
  • 基于肌酐的结局分析提示存在均值回归。
  • 在TRANSCEND中,肾小球滤过率急性变化与替米沙坦的肾脏或心血管获益之间无交互作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为事后分析。
  • 肾小球滤过率急性变化与结局风险的关联多为无统计学显著的趋势。
  • 基于肌酐的结局分析提示存在均值回归。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Initiation of blockade of the renin-angiotensin system may cause an acute decrease in glomerular filtration rate (GFR): the prognostic significance of this is unknown. We did a post hoc analysis of patients with, or at risk for, vascular disease, in two randomized controlled trials: Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and the Telmisartan Randomized AssessmeNt Study in ACE iNtolerant participants with cardiovascular Disease (TRANSCEND), whose median follow-up was 56 months. In 9340 patients new to renin-angiotensin system blockade, who were then randomized to renin-angiotensin system blockade, a fall in GFR of 15% or more at 2 weeks after starting renin-angiotensin system blockade was seen in 1480 participants (16%), with persistence at 8 weeks in 700 (7%). Both acute increases and decreases in GFR after initiation of renin-angiotensin system blockade were associated with tendencies, mostly not statistically significant, to increased risk of cardiovascular outcomes, which occurred in 1280 participants, and of microalbuminuria, which occurred in 864. Analyses of creatinine-based outcomes were suggestive of regression to the mean. In more than 3000 patients randomized in TRANSCEND to telmisartan or placebo, there was no interaction between acute change in GFR and renal or cardiovascular benefit from telmisartan. Thus, both increases and decreases in GFR on initiation of renin-angiotensin system blockade are common, and may be weakly associated with increased risk of cardiovascular and renal outcomes. Changes do not predict increased benefit from therapy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2016. PMID: 27927602. doi:10.1016/j.kint.2016.09.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。